AstraZeneca's FLAURA2 Phase III trial showed its lung cancer drug Tagrisso with chemotherapy extended survival to 47.5 months, nearly 10 months longer than Tagrisso alone. The combo cut death risk by 23%, with benefits across patient groups. Safety remained manageable. Oncology sales rose 18% in Q2, while Tagrisso revenue climbed 13%. Stock is up 27% YTD.